Response to reintroduction of cetuximab in 5 patients with advanced, chemotherapy-resistant, colorectal cancer without progressive disease following first-line therapy with a cetuximab-containing regimen.

Abstract

OBJECTIVE:

We aimed to determine the response to cetuximab in advanced, chemotherapy-resistant, colorectal cancer following successful first-line therapy with the antibody.

METHODS:

Five patients with metastatic colorectal cancer were treated with a cetuximab-containing regimen after failure of several conventional chemotherapies.

RESULTS:

These patients had been successfully treated with cetuximab as first-line therapy, and the antibody was then discontinued without disease progression. No severe toxicities were observed upon reexposure to cetuximab. Partial response was noted in 1 patient and tumor stabilization in 2 patients.

CONCLUSION:

Reintroduction of cetuximab in combination with chemotherapy is safe and efficacious in patients with colorectal cancer whose tumors were not refractory to a prior cetuximab-containing therapy.

• Authors: Volker Kaechele, Goetz von Wichert, Guido Adler, Thomas Seufferlein
• Journal: Oncology (Oncology) Vol. 74 Issue 3-4 Pg. 123-6 ( 2008) ISSN: 1423-0232 [Electronic] Switzerland
• PMID: 18708729 (Publication Type: Journal Article)
• Copyright: (c) 2008 S. Karger AG, Basel.

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents
• ErbB Receptors
• Cetuximab

Topics

• Aged
• Aged, 80 and over
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cetuximab
• Clinical Trials, Phase I as Topic
• Clinical Trials, Phase II as Topic
• Colorectal Neoplasms (drug therapy, metabolism, secondary)
• Disease Progression
• Drug Resistance, Neoplasm
• ErbB Receptors (antagonists & inhibitors)
• Female
• Humans
• Male
• Middle Aged
• Salvage Therapy
• Treatment Outcome